Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALNY NASDAQ:QDEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALNYAlnylam Pharmaceuticals$466.56-0.4%$398.78$205.87▼$484.21$61.20B0.32972,549 shs234,310 shsQDELQuidelOrtho$29.17-2.6%$26.97$22.05▼$49.45$1.98B0.141.30 million shs539,611 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALNYAlnylam Pharmaceuticals-0.16%+3.32%+8.99%+52.14%+78.91%QDELQuidelOrtho+8.36%+7.74%+18.86%+3.60%-33.24%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALNYAlnylam Pharmaceuticals$466.56-0.4%$398.78$205.87▼$484.21$61.20B0.32972,549 shs234,310 shsQDELQuidelOrtho$29.17-2.6%$26.97$22.05▼$49.45$1.98B0.141.30 million shs539,611 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALNYAlnylam Pharmaceuticals-0.16%+3.32%+8.99%+52.14%+78.91%QDELQuidelOrtho+8.36%+7.74%+18.86%+3.60%-33.24%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALNYAlnylam Pharmaceuticals 2.85Moderate Buy$421.28-9.70% DownsideQDELQuidelOrtho 2.33Hold$39.2034.38% UpsideCurrent Analyst Ratings BreakdownLatest QDEL and ALNY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/11/2025ALNYAlnylam PharmaceuticalsEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$280.00 ➝ $515.059/5/2025ALNYAlnylam PharmaceuticalsBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$450.00 ➝ $470.009/2/2025ALNYAlnylam PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$570.009/2/2025ALNYAlnylam PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$527.00 ➝ $583.008/7/2025ALNYAlnylam PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$500.00 ➝ $570.008/7/2025QDELQuidelOrthoUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$29.00 ➝ $26.008/6/2025ALNYAlnylam PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$348.00 ➝ $475.008/6/2025QDELQuidelOrthoCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$50.00 ➝ $40.008/4/2025ALNYAlnylam PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$490.008/4/2025ALNYAlnylam PharmaceuticalsWolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderperform ➝ Peer Perform8/1/2025ALNYAlnylam PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Outperform$342.00 ➝ $450.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALNYAlnylam Pharmaceuticals$2.25B27.20N/AN/A$0.52 per share897.22QDELQuidelOrtho$2.74B0.72$37.40 per share0.78$44.38 per share0.66Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALNYAlnylam Pharmaceuticals-$278.16M-$2.47N/A524.22N/A-12.96%-273.52%-7.39%10/30/2025 (Estimated)QDELQuidelOrtho-$2.05B-$6.54N/A9.09N/A-16.10%5.29%2.43%11/6/2025 (Estimated)Latest QDEL and ALNY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025QDELQuidelOrtho$0.0122$0.12+$0.1078-$3.77$612.36 million$613.90 million7/31/2025Q2 2025ALNYAlnylam Pharmaceuticals-$0.54$0.32+$0.86-$0.51$633.54 million$773.69 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALNYAlnylam PharmaceuticalsN/AN/AN/AN/AN/AQDELQuidelOrthoN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALNYAlnylam Pharmaceuticals4.102.802.75QDELQuidelOrtho0.741.120.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALNYAlnylam Pharmaceuticals92.97%QDELQuidelOrtho99.00%Insider OwnershipCompanyInsider OwnershipALNYAlnylam Pharmaceuticals1.50%QDELQuidelOrtho0.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALNYAlnylam Pharmaceuticals2,230131.08 million129.11 millionOptionableQDELQuidelOrtho6,60067.90 million67.36 millionOptionableQDEL and ALNY HeadlinesRecent News About These CompaniesRBC Capital Raises PT on QuidelOrtho Corporation From $60 to $62, Keeps Buy RatingSeptember 10 at 2:10 AM | insidermonkey.comFocus Partners Advisor Solutions LLC Invests $380,000 in QuidelOrtho Corporation $QDELSeptember 8, 2025 | marketbeat.comQuidelOrtho Corporation (NASDAQ:QDEL) Receives Consensus Recommendation of "Hold" from BrokeragesSeptember 8, 2025 | marketbeat.comQuidelOrtho Corporation $QDEL Stock Holdings Raised by AQR Capital Management LLCSeptember 7, 2025 | marketbeat.comQuidelOrtho Corporation (NASDAQ:QDEL) Given Consensus Recommendation of "Hold" by AnalystsSeptember 7, 2025 | americanbankingnews.comQuidelOrtho Corporation $QDEL Shares Sold by Magnetar Financial LLCSeptember 5, 2025 | marketbeat.comQUIDELORTHO ALERT: Bragar Eagel & Squire, P.C. is Investigating QuidelOrtho Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmSeptember 4, 2025 | globenewswire.com67,619 Shares in QuidelOrtho Corporation $QDEL Purchased by Birchview Capital LPSeptember 4, 2025 | marketbeat.comHBK Investments L P Has $16.88 Million Stock Holdings in QuidelOrtho Corporation $QDELSeptember 3, 2025 | marketbeat.comQuidelOrtho Corporation $QDEL Holdings Increased by Paradigm Capital Management Inc. NYSeptember 2, 2025 | marketbeat.comIeq Capital LLC Increases Holdings in QuidelOrtho Corporation $QDELAugust 31, 2025 | marketbeat.comRussell Investments Group Ltd. Has $1.42 Million Holdings in QuidelOrtho Corporation $QDELAugust 30, 2025 | marketbeat.comQuidelOrtho to Participate in the Baird 2025 Global Healthcare ConferenceAugust 28, 2025 | prnewswire.comJump Financial LLC Boosts Stake in QuidelOrtho Corporation $QDELAugust 28, 2025 | marketbeat.com221,658 Shares in QuidelOrtho Corporation $QDEL Acquired by Nuveen LLCAugust 27, 2025 | marketbeat.comQuidelOrtho Completes Major Debt Refinancing TransactionAugust 23, 2025 | theglobeandmail.comT. Rowe Price Investment Management Inc. Has $400.31 Million Stock Holdings in QuidelOrtho Corporation $QDELAugust 23, 2025 | marketbeat.comQuidelOrtho Corporation: QuidelOrtho Completes Debt RefinancingAugust 22, 2025 | finanznachrichten.deAmerican Century Companies Inc. Increases Stock Holdings in QuidelOrtho Corporation $QDELAugust 22, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Has $28.99 Million Stock Holdings in QuidelOrtho Corporation $QDELAugust 22, 2025 | marketbeat.comQuidelOrtho Completes Debt Refinancing | QDEL Stock NewsAugust 21, 2025 | gurufocus.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQDEL and ALNY Company DescriptionsAlnylam Pharmaceuticals NASDAQ:ALNY$466.56 -2.03 (-0.43%) As of 01:45 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.QuidelOrtho NASDAQ:QDEL$29.17 -0.77 (-2.57%) As of 01:45 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Intel's Silent Comeback: 3 Pillars the Market Is Overlooking Palantir’s Defense Partnerships Fuel Its Growth Story It May Be Time to Buy the Dip in Texas Instruments Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
